Q2 EPS Forecast for Daré Bioscience Boosted by Analyst

Daré Bioscience, Inc. (NASDAQ:DARE) – Equities research analysts at Brookline Capital Management raised their Q2 2025 earnings estimates for shares of Daré Bioscience in a report released on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now forecasts that the biotechnology company will post earnings of ($0.48) per share for the quarter, up from their previous forecast of ($0.62). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.57) EPS and FY2025 earnings at ($2.03) EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, April 1st.

Daré Bioscience Stock Up 0.3%

Daré Bioscience stock opened at $2.89 on Friday. The stock has a market cap of $25.58 million, a P/E ratio of -4.89 and a beta of 1.20. Daré Bioscience has a twelve month low of $2.67 and a twelve month high of $7.56. The company’s 50-day moving average price is $2.92 and its two-hundred day moving average price is $3.16.

Daré Bioscience (NASDAQ:DARE) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.60 million. During the same period in the previous year, the company posted ($0.84) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of Daré Bioscience during the 4th quarter worth approximately $52,000. Renaissance Technologies LLC boosted its position in Daré Bioscience by 6.7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares in the last quarter. Geode Capital Management LLC boosted its position in Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares in the last quarter. Finally, AMH Equity Ltd lifted its holdings in shares of Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the period. 6.70% of the stock is owned by institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.